U.S. Markets closed
  • S&P 500

    4,532.76
    -44.35 (-0.97%)
     
  • Dow 30

    35,028.65
    -339.82 (-0.96%)
     
  • Nasdaq

    14,340.25
    -166.64 (-1.15%)
     
  • Russell 2000

    2,062.78
    -33.44 (-1.60%)
     
  • Crude Oil

    86.63
    +1.20 (+1.40%)
     
  • Gold

    1,842.00
    +29.60 (+1.63%)
     
  • Silver

    24.22
    +0.73 (+3.10%)
     
  • EUR/USD

    1.1348
    +0.0018 (+0.1589%)
     
  • 10-Yr Bond

    1.8270
    -0.0380 (-2.04%)
     
  • Vix

    23.82
    +1.03 (+4.52%)
     
  • GBP/USD

    1.3617
    +0.0019 (+0.1389%)
     
  • USD/JPY

    114.2640
    -0.3210 (-0.2801%)
     
  • BTC-USD

    41,739.48
    -251.72 (-0.60%)
     
  • CMC Crypto 200

    991.80
    -2.94 (-0.30%)
     
  • FTSE 100

    7,589.66
    +26.11 (+0.35%)
     
  • Nikkei 225

    27,467.23
    -790.02 (-2.80%)
     

Nektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial Markets

·1 min read

SAN FRANCISCO, April 27, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2021 on Thursday, May 6, 2021, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

(PRNewsfoto/Nektar Therapeutics)
(PRNewsfoto/Nektar Therapeutics)

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through Thursday, May 27, 2021.

To access the conference call, follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Conference ID: 9233368 (Nektar Therapeutics is the host)

About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contacts:

For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-first-quarter-2021-on-thursday-may-6-2021-after-close-of-us-based-financial-markets-301278444.html

SOURCE Nektar Therapeutics